Results from the phase 3 HERO trial(NCT03085095), presented during the 2020 
American Society of Clinical Oncology Virtual Scientific Program, indicated that 
relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in 
sustained testosterone suppression through 48 weeks, fast testosterone recovery 
after discontinuation, and a 50% reduction in major adverse cardiovascular 
events (MACE) in patients with advanced prostate cancer.